A fixed-dose combination topical medication for psoriasis, combining a vitamin D3 analogue (calcipotriol) with a super-potent topical corticosteroid (clobetasol propionate). This combination offers synergistic action: calcipotriol normalizes keratinocyte differentiation and proliferation, while clobetasol provides potent anti-inflammatory, immunosuppressive, and antiproliferative effects. It is a first-line treatment for moderate to severe plaque psoriasis in adults, offering superior efficacy and faster onset compared to monotherapy, while potentially reducing the risk of steroid-induced atrophy and calcipotriol-induced irritation.
Adult: Apply a thin layer once daily to the affected areas. Maximum recommended dose: Not more than 100 grams per week. Treatment area should not exceed 30% of body surface area.
Note: Apply to psoriatic plaques only, avoiding surrounding healthy skin, face, flexures, and genital areas. Wash hands before and after application. Do not use with occlusive dressings unless directed by a physician. Do not apply to broken or infected skin. Shake the bottle well if using a suspension or lotion.
The combination exerts a synergistic effect on plaque psoriasis by targeting multiple pathogenic pathways: abnormal keratinocyte proliferation/differentiation and immune-mediated inflammation.
Pregnancy: Category C (US FDA). Adequate human studies lacking. Topical corticosteroids, especially potent ones, can be absorbed in amounts sufficient to cause systemic effects in animal studies. Use only if potential benefit justifies potential risk to the fetus. Avoid large doses, prolonged use, or occlusive dressings.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids | Increased risk of skin atrophy and systemic steroid effects. | Major |
| Topical Retinoids (Tretinoin, Adapalene) | May increase skin irritation. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May increase systemic levels of clobetasol if absorbed, increasing risk of steroid side effects. | Moderate |
| Diuretics (especially Thiazides) | May exacerbate hypercalcemia risk with calcipotriol. | Moderate |
| Cardiac Glycosides (Digoxin) | Hypercalcemia may potentiate digoxin toxicity. | Moderate |
Same composition (Calcipotriol (0.005% w/w) + Clobetasol (0.05% w/w)), different brands: